Short Interest in Daxor Corporation (NASDAQ:DXR) Declines By 38.7%

Daxor Corporation (NASDAQ:DXR) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totaling 1,276 shares, a decrease of 38.7% from the June 15th total of 2,083 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 3,122 shares, the days-to-cover ratio is presently 0.4 days.

Daxor Price Performance

Shares of NASDAQ:DXR traded up $0.81 on Friday, reaching $11.41. The company’s stock had a trading volume of 787 shares, compared to its average volume of 7,741. The stock’s 50-day moving average is $10.36 and its two-hundred day moving average is $11.23. Daxor has a 52-week low of $8.56 and a 52-week high of $14.76.

Daxor (NASDAQ:DXR) last announced its earnings results on Monday, March 2nd. The company reported ($0.10) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Daxor in a research report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Daxor has a consensus rating of “Moderate Buy”.

Institutional Trading of Daxor

Hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. purchased a new position in shares of Daxor in the 2nd quarter valued at approximately $86,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Daxor in the fourth quarter valued at approximately $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in shares of Daxor during the first quarter worth approximately $245,000. Crescent Grove Advisors LLC purchased a new stake in shares of Daxor during the first quarter worth approximately $104,000. Finally, Aristides Capital LLC acquired a new stake in shares of Daxor during the first quarter worth $403,000. 1.34% of the stock is owned by institutional investors and hedge funds.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA?100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA?100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.